{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T08:46:04Z","timestamp":1785746764596,"version":"3.56.0"},"reference-count":46,"publisher":"Informa UK Limited","issue":"7","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"published-print":{"date-parts":[[2026,7,3]]},"DOI":"10.1080\/17425255.2026.2710110","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:08:37Z","timestamp":1784898517000},"page":"483-494","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Inavolisib: a second-generation PI3K\u03b1 inhibitor in HR+\/HER2-negative breast cancer"],"prefix":"10.1080","volume":"22","author":[{"given":"Elaria","family":"Abdy","sequence":"first","affiliation":[{"name":"Kean University","place":["Union, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Betancourt","sequence":"additional","affiliation":[{"name":"Kean University","place":["Union, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9411-2091","authenticated-orcid":false,"given":"Supratik","family":"Kar","sequence":"additional","affiliation":[{"name":"Kean University","place":["Union, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182397"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13123611"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00510"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10078-5"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104437"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c01422"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/852748"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.2174\/1871520616666160502122724"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00523-4"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.70100"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.46747\/cfp.6804271"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231205848"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.2174\/156800908786733504"},{"key":"e_1_3_5_16_1","volume-title":"StatPearls [Internet]","author":"Patel P","year":"2026","unstructured":"Patel P, Jacobs TF. Tamoxifen. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 [2025 Mar 28]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK532905\/"},{"key":"e_1_3_5_17_1","unstructured":"Arimidex (anastrozole) tablet label from U.S. Food and Drug Administration. 2010 Oct 10. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020541s026lbl.Pdf"},{"key":"e_1_3_5_18_1","unstructured":"Aromasin (exemestane) tablet label from U.S. Food and Drug Administration. 2005 Oct 4. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/020753s006lbl.pdf"},{"key":"e_1_3_5_19_1","unstructured":"Femara (letrozole) tablet label from U.S. Food and Drug Administration. 2024 Dec. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/020726s027lbl.pdf"},{"key":"e_1_3_5_20_1","unstructured":"Afinitor (everolimus) tablet label from U.S. Food and Drug Administration. 2012 Jul. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022334s016lbl.pdf"},{"key":"e_1_3_5_21_1","unstructured":"ZOLADEX\u00ae (goserelin acetate implant) label from U.S. Food and Drug Administration. 2009 Aug 13. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/019726s050s051s052lbl.pdf"},{"key":"e_1_3_5_22_1","unstructured":"VERZENIO\u00ae (abemaciclib) tablets for oral use label from U.S. Food and Drug Administration. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/208716s006s007s008lbl.pdf"},{"key":"e_1_3_5_23_1","unstructured":"KISQALI\u00ae (ribociclib) tablet label from U.S. Food and Drug Administration. 2024 Sep. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/209092s019lbl.pdf"},{"key":"e_1_3_5_24_1","unstructured":"IBRANCE\u00ae (palbociclib) capsules for oral use label from U.S. Food and Drug Administration. 2019 Apr. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/207103s021 212436s009lbl.pdf"},{"key":"e_1_3_5_25_1","unstructured":"FASLODEX\u00ae (fulvestrant) injection label from U.S. Food and Drug Administration. 2019 May. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021344Orig1s039lbl.pdf"},{"key":"e_1_3_5_26_1","unstructured":"ENHERTU\u00ae (fam-trastuzumab deruxtecan-nxki) for injection for intravenous use injection label from U.S. Food and Drug Administration. 2024 Apr. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761139s028lbl.pdf"},{"key":"e_1_3_5_27_1","unstructured":"TRODELVY\u00ae (sacituzumab govitecan-hziy) for injection label from U.S. Food and Drug Administration. 2025 Mar. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761115s009lbl.pdf"},{"key":"e_1_3_5_28_1","unstructured":"DATROWAY\u00ae (datopotamab deruxtecan-dlnk) for injection label from U.S. Food and Drug Administration. 2025 Jan. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761394s000lbl.pdf"},{"key":"e_1_3_5_29_1","unstructured":"Piqray (alpelisib) tablet label from U.S. Food and Drug Administration. 2019 May. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212526s000lbl.pdf"},{"key":"e_1_3_5_30_1","unstructured":"TRUQAP (capivasertib) tablet label from U.S. Food and Drug Sdministration. 2023 Nov. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/218197s000lbl.pdf"},{"key":"e_1_3_5_31_1","unstructured":"Itovebi (inavolisib) tablet label from U.S. Food and Drug Administration. 2024 Oct. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/219249s001lbl.pdf"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.28"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI41680"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa4442"},{"key":"e_1_3_5_35_1","unstructured":"European Medicines Agency. Itovebi: European Public Assessment Report (EPAR); 2025. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/itovebi"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.5831"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00613-0"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404625"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0072"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103465"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00218-4"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00110"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.1052"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04263-8"},{"key":"e_1_3_5_45_1","unstructured":"ClinicalTrials.gov. To evaluate the safety tolerability and pharmacokinetics of inavolisib single agent in participants with solid tumors and in combination with endocrine and targeted therapies in participants with breast cancer. Bethesda (MD): U.S. National Library of Medicine; 2025 Mar 18. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03006172"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS1136"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS23-PO2-19-09"},{"key":"e_1_3_5_48_1","unstructured":"Hoffmann-La Roche INAVO123. A study evaluating the efficacy and safety of inavolisib plus CDK4\/6 inhibitor and letrozole vs placebo + CDK4\/6i and letrozole in participants with endocrine-sensitive PIK3CA-Mutated hormone receptor-positive HER2-negative advanced breast cancer. Available from: https:\/\/genentech-clinicaltrials.com\/en\/trials\/cancer\/bc\/a-study-evaluating-the-efficacy-and-safety-of-inavolisi-81795.for-patient.html"}],"container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2026.2710110","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/17425255.2026.2710110","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2026.2710110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T08:04:23Z","timestamp":1785744263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2026.2710110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,3]]}},"alternative-id":["10.1080\/17425255.2026.2710110"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2026.2710110","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}